Fang Xie, Ph.D.

Fang Xie, Ph.D.: Attorney with Greenberg Traurig, LLP
  • Shareholder at Greenberg Traurig, LLP (2021 Attorneys)
  • One International Place, Boston, MA 02110
    View Fang Xie, Ph.D.'s office location
  • Peer Reviews

    No Reviews
  • Profile Visibility [ i ]
    • #516 in weekly profile views out of 19,462 Attorneys in Boston, MA
    • #46,947 in weekly profile views out of 1,822,215 total attorneys Overall

Biography

Fang Xie, Ph.D., co-leads the firm’s Biotechnology and Pharmaceutical Group. Listed in IAM Strategy 300 - The World’s Leading IP Strategists, Fang focuses her practice on establishing, defending, licensing, sharing and monetizing intellectual property rights for life sciences companies. She has broad experience in worldwide patent portfolio development, intellectual property due diligence, licensing and technology transfer, patentability and product clearance studies, validity/invalidity analyses, patent infringement evaluations, as well as intellectual property litigation and pre-litigation counseling.

Fang’s primary technical areas include biotechnology, synthetic biology and pharmaceuticals, with a focus on immunotherapy, antibody and biologics/biosimilars, nucleic acid synthesis, gene editing, protein and organism engineering, stem cell technology, biomarkers, diagnostics, small molecule drugs, regenerative medicine, analytical chemistry and cosmetics.

Fang’s typical clients are biopharmaceutical companies at various stages, universities and research institutes, as well as venture capital and institutional investors. Representative clients include a number of venture-backed biopharma startups, a publicly-traded biosynthetic chemistry company, a publicly-traded regenerative medicine company, as well as a number of top tier academic research institutions such as the Whitehead Institute for Biomedical Research, University of Texas Southwestern Medical Center, California Institute of Technology, and the Chinese Academy of Sciences. Fang also frequently works with early-stage biopharmaceutical companies to enhance their IP position and develop licensing and partnership strategies.

Fang’s recent experience includes serving on the litigation team representing a large international pharmaceutical company in a patent infringement action related to certain biomarkers used in drug discovery, as well as investigating a trade secret misappropriation on behalf of a global energy company.

Prior to entering the field of law, Fang conducted her doctoral research at MIT, in the laboratories of Nobel Laureate H. Robert Horvitz and U.S. National Academy of Sciences Member Terry Orr-Weaver. At MIT, she investigated programmed cell death, developmental DNA replication, and gene amplification. She also received post-doctoral training at the Whitehead Institute for Biomedical Research in the areas of genomics, epigenetics, small RNA, and cancer biology. Prior to attending MIT, she had experience studying neuron regeneration and chromosomal evolution.

While at MIT, Fang also assisted a start-up medical device company in managing its patent portfolio, evaluating diagnostic technologies, and drafting patent applications.

Concentrations

•Life sciences
•Pharmaceuticals
•Biologics
•Synthetic biology and industrial biotechnology
•Patent law
•Licensing and technology transfer transactions
•Intellectual property litigation

Recognition & Leadership

Awards & Accolades

•Listed, IAM Strategy 300 - The World’s Leading IP Strategists, 2016-2018
•Listed, LMG Life Sciences, Life Science Star, 2017-2018

Areas of Practice (3)

  • Intellectual Property & Technology
  • Life Sciences & Medical Technology
  • Patent Prosecution

Education & Credentials

Contact Information:
617.310.5273  Phone
617.310.6001  Fax
www.gtlaw.com/People/fangxie
University Attended:
Peking University, B.S., summa cum laude, 2001; Massachusetts Institute of Technology, Ph.D., Biology, MIT Presidential Fellow, Keck Graduate Fellow, 2007
Law School Attended:
Suffolk University Law School, J.D., cum laude, International Law Concentration with Distinction, 2012
Year of First Admission:
2012
Admission:
U.S. Patent and Trademark Office; 2012, Massachusetts
Memberships:

Professional & Community Involvement

•Member, Bayhelix, Chinese Business Leaders in Life Sciences
•Member, American Bar Association
•Member, Boston Bar Association
•Member, Boston Patent Law Association
•Member, Women Entrepreneurs in Science and Technology
•Member, Genetics Society of America
•Member, American Association of the Advancement of Science
•Member, The Sigma Xi Scientific Research Honor Society

Languages:
Chinese (Mandarin) and Native
Reported Cases:
Experience: Representative Matters: Represented Jiangsu Hengrui Medicine Co. Ltd. in out-licensing of its JAK inhibitor drug, SHR0302 to Arcutis, Inc.; Represented CSPC Pharmaceutical Group Limited in multiple licensing transactions with U.S. universities and companies to obtain rights to various cancer therapeutics.; Represented Shenzhen Beike Biotechnology Co., Ltd., a leading Chinese cell-based therapy company, in a license agreement with Altor BioScience Corporation (Altor), a U.S.-based developer of novel cancer immunotherapies, to develop and commercialize Altor's proprietary Interleukin-15 based superagonist complex, in China.; Represented public company Huapont Life Sciences Co. Ltd. in a number of strategic investment and licensing deals in the U.S.; Represented HitGen Ltd., leader in DNA-encoded library technology in China, in a number of transactions with U.S. pharmaceutical companies including Merck, Pfizer, Monsanto, BASF, Amgen, Sanofi, Takeda, Shire, Boehringer, Celgene, etc.; Represented Shanghai Jingfeng Pharmaceutical Company in a licensing deal with Carbylan Biosurgery, Inc. where Jingfeng acquired rights to Carbylan's Hydros-TA technology and related products for the Greater China territory.; Represented Adagene (Suzhou) Limited in a number of licensing and joint development deals with various foreign biotech and pharmaceutical companies.; Represented Innovent Biologics (Suzhou) Co., Ltd. in negotiating and finalizing a number of licensing agreements with various foreign biotech and pharmaceutical companies.; Represented Zhongyuan Union Cell & Gene in its $300mm acquisition of OriGene Technologies, Inc., a U.S. gene and antibody product company.
ISLN:
921280239

Peer Reviews

This lawyer does not have peer reviews.

*Peer Reviews provided before April 15, 2008 are not displayed.

Documents (2)

Documents by this lawyer on Martindale.com

Boston, Massachusetts

Contact Fang Xie, Ph.D.

Required Fields

Required Fields


By clicking on the "Submit" button, you agree to the Terms of Use, Supplemental Terms and Privacy Policy. You also consent to be contacted at the phone number you provided, including by autodials, text messages and/or pre-recorded calls, from Martindale and its affiliates and from or on behalf of attorneys you request or contact through this site. Consent is not a condition of purchase.

You should not send any sensitive or confidential information through this site. Emails sent through this site do not create an attorney-client relationship and may not be treated as privileged or confidential. The lawyer or law firm you are contacting is not required to, and may choose not to, accept you as a client. The Internet is not necessarily secure and emails sent though this site could be intercepted or read by third parties.